Publications

350 publications

Enter search criteria

Fill in keyword(s) to narrow your search.

Period from
to

Enter a start and/or end date here, using the following format: DD-MM-YYYY.

You can select a specific type of a publication you are looking for, such as press releases or speeches

Sort by: Date / Relevance

GVS advice on ferrimaltol (Feraccru®) for treating iron deficiency

Zorginstituut Nederland recommends that ferrimaltol (Feraccru®) should not be included in the Medicine Reimbursement System ...

Report | 26-07-2021

GVS advice on subcutaneous buprenorphine (Buvidal®)

Zorginstituut Nederland has completed its assessment whether the product subcutaneous buprenorphine (Buvidal®) is interchangeable ...

Report | 21-07-2021

Package advice for the lock procedure drug betibeglogene autotemcel (Zynteglo®)

The National Health Care Institute has completed its assessment whether betibeglogene autotemcel (Zynteglo®) can be included in ...

Report | 21-07-2021

Package advice on avelumab (Bavencio®) for treating urothelial cell carcinoma

Zorginstituut Nederland has completed its assessment whether avelumab (Bavencio®) can be included in the insured package. ...

Report | 21-07-2021

Package advice on entrectinib (Rozlytrek®) for the treatment of ROS1 fusion-positive advanced non-small cell lung cancer

Zorginstituut Nederland has completed its assessment whether entrectinib (Rozlytrek®) can be included in the insured package. The ...

Report | 21-07-2021

GVS advice for cladribine (Mavenclad®) – extension of further conditions

The National Health Care Institute has completed its reassessment whether the further conditions of cladribine (Mavenclad®) could ...

Report | 05-07-2021

GVS assessment of calcifediol (Hidroferol®)

Zorginstituut Nederland has completed its assessment whether calcifediol (Hidroferol®) is interchangeable with a medicine already ...

Report | 01-07-2021

Package advice niraparib (Zejula®)

Zorginstituut Nederland has completed its assessment whether niraparib (Zejula®) can be included in the insured package. ...

Report | 24-06-2021

GVS advice SGLT-2 inhibitors

The National Health Care Institute has completed its assessment the further conditions of SGLT-2 inhibitors canagliflozin ...

Report | 22-06-2021

GVS advice RZV (Shingrix®) for the prevention of herpes zoster and related post-herpetic neuralgia

Zorginstituut Nederland has completed its assessment whether the recombinant herpes zoster vaccine with adjuvant (RZV, Shingrix®) ...

Report | 14-06-2021